Francesc X. Bosch

Francesc X. Bosch

Avda. Gran Via 199-203
Barcelona, CT 08908, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 250 publications

Tumoral immune microenvironment profiling in B-cell non-Hodgkin lymphoma stratifies patients in different prognostic groups.

Tumoral immune microenvironment profiling in B-cell non-Hodgkin lymphoma stratifies patients in different prognostic groups.

Journal: Frontiers in immunology

Published: May 15, 2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: May 06, 2026

Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.

Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.

Journal: Blood advances

Published: April 07, 2026

Prolonged SARS-CoV-2 infection in hematologic malignancies: clinical impact, risk factors and intra-host viral evolution.

Prolonged SARS-CoV-2 infection in hematologic malignancies: clinical impact, risk factors and intra-host viral evolution.

Journal: Frontiers in immunology

Published: April 02, 2026

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation.

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation.

Journal: HemaSphere

Published: February 06, 2026

Response to the letter to the editor entitled "The precision of a report on precision".

Response to the letter to the editor entitled "The precision of a report on precision".

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: December 25, 2025

Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial.

Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial.

Journal: Nature medicine

Published: December 15, 2025

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine

Published: December 08, 2025

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Journal: Blood advances

Published: December 04, 2025

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Journal: Blood advances

Published: December 04, 2025

How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

Journal: Leukemia

Published: November 08, 2025

Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.

Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.

Journal: British journal of haematology

Published: November 03, 2025

Showing 1-12 of 250

Last Updated: 09/26/2026